Sobi's Gamifant Shows Promise in Phase 2a Study for IFN-γ-Driven Sepsis, Stock Climbs

BearMarketBard · 2026-01-12T17:03:35+00:00

Sobi's Phase 2a EMBRACE trial for Gamifant showed significant improvements in organ function and survival in patients with IFN-γ-driven sepsis. This breakthrough may lead to tailored treatments for this critical patient group.

BearMarketBard

2026-01-12 17:03:35

Abstract generation in progress

Swedish Orphan Biovitrum AB (Sobi) reported encouraging topline results from its Phase 2a EMBRACE trial evaluating Gamifant (emapalumab) as a potential treatment for interferon-gamma (IFN-γ)-driven sepsis (IDS). The biotech company’s shares responded positively, closing at SEK 337.60 in Stockholm trading, reflecting a gain of SEK 3.80 or 1.14%.

Study Validates Novel Treatment Approach

The EMBRACE study, conducted in partnership with the Hellenic Institute for the Study of Sepsis (HISS), demonstrated proof-of-concept results that showed meaningful improvements in organ function and survival rates among patients with IDS. These findings represent a significant step toward addressing a previously underrecognized patient population facing severe clinical challenges.

Understanding IFN-γ-Driven Sepsis

Recent research published in eBioMedicine during 2024 unveiled distinct sepsis subtypes, with approximately 20% of patients identified as having the newly characterized IFN-γ-driven sepsis endotype. This subset of sepsis patients exhibits elevated CXCL9 markers, measurable interferon-gamma presence, and notably poor prognoses. Historical data indicates 28-day mortality rates ranging between 40% to 43% in this population—substantially higher than traditional sepsis classifications.

Sepsis itself remains one of the world’s leading causes of mortality, triggered by severe infections that cascade into multi-organ failure. The identification of distinct endotypes has underscored the critical need for tailored treatment strategies rather than one-size-fits-all approaches.

Path Forward

Building on the EMBRACE trial’s encouraging outcomes, Sobi and HISS intend to accelerate emapalumab development for IDS treatment. The companies plan to engage with regulatory bodies to chart the appropriate next phases of clinical development. Comprehensive data from the EMBRACE study will be presented at a forthcoming medical conference, with additional updates provided as the program progresses.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.